Vanguard Global Advisers
IMMX icon

Vanguard Global Advisers’s Immix Biopharma IMMX Stock Holding History

Vanguard Global Advisers’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Buy
22,095
+2,353
+12% +$21.8K ﹤0.01% 2449
2026
Q1 		$180K Buy
+19,742
New +$145K ﹤0.01% 2485

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Global Advisers's IMMX Position: Q2 2026 in Review

Vanguard Global Advisers increased its Immix Biopharma (IMMX) stake by 12% in Q2 2026, buying an estimated $21.8K and bringing the position to 22,095 shares worth $228K. The position accounts for ﹤0.01% of the portfolio, ranked #2449.

Vanguard Global Advisers first reported a position in IMMX in Q1 2026 and has held it in 2 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Vanguard Global Advisers held 22,095 shares of Immix Biopharma worth $228K as of Q2 2026.
  • Vanguard Global Advisers bought 2,353 Immix Biopharma shares in Q2 2026, an estimated $21.8K.
  • Immix Biopharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2449 holding.
  • Vanguard Global Advisers first reported a position in Immix Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.